Canterbury DHB


Chronic Myeloid Leukaemia

SCT is now rarely done following the introduction of imatinib and related drugs. For the patient who fails to respond to imatinib, relapses through imatinib treatment, or is not suitable for this drug, allografting will need to be considered, as well as the use of an alternative more active tyrosine kinase inhibitor.

In This Section

Standard Allografts


Standard Allografts

This is performed following either:


If a RIC SCT is done for CML then Fludarabine/Melphalan/Alemtuzumab conditioning could be used.

About this Canterbury DHB document (9179):

Document Owner:

Andrew Butler (see Who's Who)

Last Reviewed:

December 2016

Next Review:

December 2018


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 9179